ClinicalTrials.gg
RecruitingNCT06594588Updated Jul 2, 2025

Individualized Exploration of Aerobic Exercise-assisted Treatment of Depression

An interventional study of Aerobic exercise in Depression - Major Depressive Disorder, sponsored by Peking University. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Peking University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Depression by Peking University — 10 open to participants now, 13 under way, none of them phase 3. Depression · Peking University.

Planned enrollment
20th of 20
80 · median 200
Started
2024
with 4 others
No phase
19 of 21
10 open now
Primary completion
2025-10
later than 5 of 12 live
Registered
8th of 21
by date

Among the 21 studies in Depression by Peking University, this one is the 20th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2024, is one of 19 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 8th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

10 of the 21 studies in Depression by Peking University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Depression by Peking University, or all of them as a file.
02

Study summary

The goal of this project is to quantify the relative effectiveness of aerobic exercise monitored by smart wristbands in assisting the treatment of depression and improving cognitive function. It aims to explore the mechanisms through which aerobic exercise exerts its effects using imaging genetics and other methods, and to identify suitable populations for exercise, ultimately providing personalized clinical exercise prescriptions. This study will intervene from a behavioral perspective and also seeks to motivate participants to change and improve their physical activity habits.

03

Conditions studied

  • Depression - Major Depressive Disorder

Keywords

  • Aerobic exercise
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-45 years (including 18 and 45), no gender restriction;
  2. Meets the diagnostic criteria for depressive disorders according to the , Fifth Edition (DSM-V);
  3. Outpatients or inpatients; Hamilton Depression Rating Scale 17-item (HAMD-17) score ≥ 14; Mood Disorder Questionnaire (MDQ) screening negative to exclude bipolar disorder patients; and Clinical Global Impressions-Severity (CGI-S) score ≥ 4;
  4. Maintained on antidepressant treatment for at least 4 weeks or not using antidepressant treatment;
  5. Written obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with other mental disorders, including schizophrenia, bipolar disorder, alcohol or substance abuse/dependence, eating disorders, etc.;
  2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness;
  3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury;
  4. Suffering from conditions with high exercise risk, such as hypertension or heart disease;
  5. Currently undergoing systematic psychological therapy;
  6. In the 3-minute step test, males with a recovery heart rate more than131 and females with a recovery heart rate more than 140;
  7. Physically restricted individuals unable to participate in physical exercise;
  8. Physical Activity Readiness Questionnaire (PAR-Q) score ≥ 2;
  9. Pregnant women or individuals with to MRI examinations;
  10. Individuals with severe suicidal tendencies or at risk of harming others.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Aerobic exercise group

    Aerobic exercise intervention combined with conventional drug treatment

    Behavioral: Aerobic exercise

  • No intervention
    Waiting control group

    Antidepressants were routinely used and aerobic exercise interventions were performed at the end of the 8-week follow-up

Interventions

  • BehavioralAerobic exercise

    Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy

06

What researchers measure

Primary outcomes

  1. Change from baseline in Hamilton Depression Rating Scale (HAMD)

    The outcome is assessed by HAMD-17 Scale.

    Time frame: Week 4 and 8 of treatment duration

Secondary outcomes

  1. Change from baseline in THINC-it score

    Time frame: Week 4 and 8 of treatment duration

  2. Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Week 4 and 8 of treatment duration

  3. Response to treatment

    The reduction rate of HAMD-17 or MADRS score was ≥50%

    Time frame: Week 4 and 8 of treatment duration

  4. Clinical Global Impression-Severity of Illness (CGI-S)

    Time frame: Week 4 and 8 of treatment duration

  5. Change from baseline in Hamilton Anxiety Rating Scale (HAMA)

    Time frame: Week 4 and 8 of treatment duration

  6. Change from baseline in Ruminative Responses Scale (RRS)

    Time frame: Week 4 and 8 of treatment duration

  7. Change from baseline in Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Week 4 and 8 of treatment duration

  8. Change from baseline in Connor-Davidson Resilience Scale (CD-RISC)

    Time frame: Week 4 and 8 of treatment duration

  9. Rating Scale for Side Effects (SERS) -Antidepressant

    Rating Scale for Side Effects (SERS) -Antidepressant

    Time frame: Week 4 and 8 of treatment duration

  10. Mood Disorder Questionnaire (MDQ)

    Time frame: Week 4 and 8 of treatment duration

  11. International Physical Activity Questionnaire (IPAQ)

    Time frame: Week 4 and 8 of treatment duration

  12. Biomarkers level

    CRP, IL-1β, TNF-α, IL-6, IL-8, IL-10 and other immune factors, irisin, neurotrophic factor BDNF, vascular endothelial growth factor VEGF, and insulin growth factor IGF-1, NLRP3, CXCL8, CXCL3, CCL5, etc

    Time frame: Week 0 and 8 of treatment duration

  13. Body weight in kilograms

    Time frame: Week 4 and 8 of treatment duration

  14. Body fat rate

    Time frame: Week 4 and 8 of treatment duration

  15. Brain imaging features

    Acquisition was performed by magnetic resonance imaging

    Time frame: Week 0 and 8 of treatment duration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Oct 2025, 13 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 13 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartActual
Sep 12, 2024
Primary completionEst.
Oct 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06594588
Lead sponsor
Peking University
Responsible party
Weihua Yue (Professor, Peking University Sixth Hospital) — Principal investigator
First posted
Sep 19, 2024
Start date
Sep 12, 2024
Primary completion
Oct 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jul 2, 2025

Study contacts

Weihua Yue, Doctor
Contact
dryue@bjmu.edu.cn
86-010-82805307
Guorui Zhao
Contact
grzhao@bjmu.edu.cn
86-13661352950

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion